Real-world experience with selinexor-containing chemotherapy-free or low-dose chemotherapy regimens for patients with relapsed/refractory acute myeloid leukemia and myeloid sarcoma

Real-world experience with selinexor-containing chemotherapy-free or low-dose chemotherapy regimens for patients with relapsed/refractory acute myeloid leukemia and myeloid sarcoma

Introduction: Treatment of relapsed or refractory acute myeloid leukemia (R/R AML) and myeloid sarcoma (MS) has presented challenges for decades. Studies on selinexor in combination with various standard or intensive chemotherapy regimens for the treatment of R/R AML have demonstrated promising resu...

Full description

Bibliographic Details
Main Authors: Xiwen Tong, Jie Jin, Bin Xu, Shuai Su, Li Li, Mengyuan Li, Yizhou Peng, Xia Mao, Wei Huang, Donghua Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Pharmacology
Subjects:
acute myeloid leukemia
selinexor
chemotherapy-free
relapsed
refractory
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1217701/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1217701/full

Similar Items